Ross Moat Sells 27,594 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) insider Ross Moat sold 27,594 shares of the company’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total transaction of $800,777.88. Following the completion of the transaction, the insider now directly owns 9,415 shares in the company, valued at approximately $273,223.30. The trade was a 74.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Ross Moat also recently made the following trade(s):

• On Monday, May 5th, Ross Moat sold 6,272 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $28.00, for a total transaction of $175,616.00.
• On Tuesday, April 29th, Ross Moat sold 64,035 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $25.21, for a total value of $1,614,322.35.
• On Thursday, May 1st, Ross Moat sold 23,234 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $28.02, for a total value of $651,016.68.
• On Monday, April 21st, Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $20.29, for a total value of $370,475.11.

Kiniksa Pharmaceuticals Stock Up 2.4%

KNSA stock opened at $30.23 on Friday. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $30.27. The firm has a market cap of $2.21 billion, a PE ratio of -215.91 and a beta of 0.06. The business has a 50 day moving average of $24.27 and a 200 day moving average of $21.90.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. During the same period last year, the business posted ($0.25) EPS. The company’s revenue was up 72.5% compared to the same quarter last year. On average, research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on KNSA. Citigroup began coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price objective for the company. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, April 29th. Wedbush restated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Finally, Wall Street Zen cut Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Kiniksa Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $38.80.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Braidwell LP lifted its position in Kiniksa Pharmaceuticals by 19.3% during the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock valued at $68,289,000 after purchasing an additional 557,934 shares in the last quarter. Vanguard Group Inc. raised its holdings in Kiniksa Pharmaceuticals by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after acquiring an additional 151,604 shares during the period. Acadian Asset Management LLC raised its holdings in Kiniksa Pharmaceuticals by 170.3% during the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock valued at $22,961,000 after acquiring an additional 651,700 shares during the period. Millennium Management LLC raised its holdings in Kiniksa Pharmaceuticals by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares during the period. Finally, Nuveen Asset Management LLC raised its holdings in Kiniksa Pharmaceuticals by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock valued at $15,737,000 after acquiring an additional 54,361 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.